Related Experiment Video
Updated: Jul 10, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
[Neuroprotective effect of dopamine agonists]
Andrzej Szczudlik1, Monika Rudzińska
1Klinika Neurologii Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie. szczudlik@neuro.cm-uj.krakow.pl
Neurologia I Neurochirurgia Polska
|October 19, 2007
Summary
Dopamine agonists may offer neuroprotection in Parkinson's disease by slowing neuronal loss. Clinical trials suggest ropinirole and pramipexole show potential, but further research is needed to confirm these effects.
Area of Science:
- Neuroscience
- Pharmacology
Context:
- Parkinson's disease (PD) is characterized by progressive neurodegeneration.
- Dopamine agonists are a key treatment for PD symptoms.
Purpose:
- To evaluate the neuroprotective potential of dopamine agonists in Parkinson's disease.
- To assess if dopamine agonists can slow neurodegeneration progression.
Summary:
- Preclinical studies indicate dopamine agonists like bromocriptine, pergolide, pramipexole, and ropinirole exhibit neuroprotective properties.
- Clinical trials using neuroimaging (fluoro-dopa PET, beta-CIT SPECT) suggest ropinirole and pramipexole may slow dopamine neuron loss compared to levodopa.
- Potential confounding factors include drug effects on imaging markers and symptomatic improvements.
Impact:
- Findings suggest dopamine agonists could be a strategy to modify Parkinson's disease progression.
- Further clinical validation is required to confirm the disease-modifying effects of dopamine agonists.
- This research may influence future therapeutic strategies for Parkinson's disease, aiming for neuroprotection beyond symptomatic relief.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...